Clinical Trials Browser

INDUSTRY × Uveal Melanoma × AP 1903 reagent × Clear all

NCT02743611 2023-10-05

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

Phase 1/2 Terminated

4 enrolled 9 charts

DermatologicMyeloidOther hematologic neoplasm

Uveal Melanoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute